Tag: ASCO
G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential...
RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from...
New Optional 100kA Short Circuit Current Rating for ASCO 4800 Load...
Florham Park, New Jersey, 05/20/2021 / SubmitMyPR /The ASCO 4800 Load Bank Models with 100kA Short Circuit Current Rating provides:
- Increased worker safety-...
Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021...
CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical...
Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid...
LOS ANGELES, May 19, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined...
NextCure to Present Trials in Progress Poster for NC410 at the...
BELTSVILLE, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing...
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018...
Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patientsCohort expansion in mCRPC: 11/22 (50%) patients have...
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society...
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) — Systemic administration of PV-10 for...